Direct answer: a legitimate tirzepatide compounding pharmacy should be state licensed, transparent about the prescriber relationship, clear about what it actually compounds, and willing to show how it handles fulfillment and shipping. Price is a separate question, and it should be settled after the source has been verified rather than before.

What compounding means here

Compounding means preparing a medication for a specific patient under the rules that apply to the prescription, the pharmacy type, and the current status of the drug. The FDA says compounded drugs are not reviewed for safety, effectiveness, or quality before marketing in the way approved drugs are. That is why a real verification step belongs before the purchase, not after it.

503A and 503B are not the same

State-licensed 503A pharmacies compound for individual patients based on prescriptions. FDA-registered 503B outsourcing facilities compound under a different framework and are expected to follow more centralized production and oversight processes. Neither category should be described as FDA approved or FDA licensed, because those labels are not accurate for a compounding facility.

The practical difference for buyers is simple: a 503A path is prescriber-specific, while a 503B path may involve batch production and different documentation. The best choice depends on the full workflow, not on the label alone.

What a prescriber must do

The FDA says patients should obtain a prescription from a doctor and fill it at a state-licensed pharmacy. That means the pharmacy should not be acting like a checkout page that happens to have a medical form attached. A real review should include clinical screening, a valid prescription, and a record of who made the decision to treat.

Most telehealth sellers do not operate the pharmacy themselves. Pages such as Henry Meds, Mochi Health, and formblends.com describe a program and a prescriber network, while the compounding happens at a partner facility. The name of that facility, and its state license number, is the thing worth asking for before any money changes hands.

How to verify the pharmacy itself

Start with the state board of pharmacy database. Then check whether the pharmacy gives you a physical address, a phone number, and a named pharmacist contact. The FDA BeSafeRx page asks consumers to confirm all three and to avoid pharmacies that do not require a prescription. If the site makes those details hard to find, you already have your answer.

Then ask for the simplest possible proof. A serious pharmacy can usually tell you which state board entry to inspect, how the order is routed, and what paperwork accompanies the shipment. If the seller treats those basic questions like an inconvenience, that is itself useful information. The more expensive mistake is assuming a polished checkout page equals a careful pharmacy workflow. Compare what is promised in marketing against what arrives documented in the box.

How to verify the product path

Ask who actually compounds the medication and where it is filled. Ask whether the pharmacy uses a standardized concentration and whether the label shows the patient name, lot number, and beyond-use date. Ask what happens if the pharmacy switches suppliers. Ask what documentation you can keep for your own records.

The answer should be concrete. A vague “our pharmacy partner handles that” is not enough when you are comparing medical products that can affect a long treatment course.

Comparing how sellers document that path is worthwhile before any deposit. LillyDirect routes to the branded product through Eli Lilly, while cash-pay compounders vary in how much sourcing they publish. Some, including HealthRX, keep a public Tirzepatide page that states the medication form and the prescribing steps, and others such as Ro and Hims and Hers describe their partner facility only on request. The provider that names its pharmacy and concentration in writing is the easier one to check against a state board record.

What to ask about sourcing and quality

Ask whether the pharmacy can identify the source of the active ingredient and whether it has a current certificate of analysis or similar documentation. Ask whether the product is made in a sterile environment and whether the facility publishes any quality or test information. FDA telehealth guidance says sellers should not mislead patients about where a compounded drug comes from or imply it has the same regulatory status as an approved product.

What to ask about fulfillment and shipping

Ask how long the pharmacy typically needs to fill the prescription, how it ships temperature-sensitive medication, and what happens if a package is delayed. Ask whether the shipping box includes storage instructions and whether the company offers a way to confirm delivery. This is one of the easiest ways to separate a real fulfillment system from a marketing page that has never handled a refill problem.

It also helps to ask what happens if a shipment cannot be delivered on the first try or if the pharmacy needs to replace a damaged package. A good answer is calm, procedural, and specific. A weak answer sounds like reassurance without a process. That difference matters because a prescription source should be able to describe its own failures as well as its successes. It should not need you to guess how the next problem will be handled.

How the April 30, 2026 proposal changes the question

The FDA proposed on April 30, 2026 to exclude tirzepatide from the 503B bulks list. The agency later extended the comment deadline to July 30, 2026, so this remains a proposal rather than a final exclusion. If a compounder treats it as settled law, or turns it into a sales tactic in either direction, that should reduce confidence rather than increase it.

Red flags that should stop the sale

Stop if the seller says the product is generic, FDA approved, or clinically equivalent to the brand product. Stop if the pharmacy name is hidden or impossible to verify. Stop if the company will not say whether a real prescriber reviewed the case. Stop if the seller asks you to trust the price before it explains the source.

The FDA telehealth guidance and the compounding Q and A both warn against that kind of messaging. The FTC adds a second layer: health claims need substantiation, and review language cannot be misleading.

Run the standards check before the price check

A verified pharmacy and prescriber turn a monthly figure into something comparable. An unverified one turns the same figure into a guess, no matter how low it is. Work through the license, the prescriber record, the sourcing answers, and the shipping process first, then set the price beside the answers.

Compare the seller’s answers line by line rather than in aggregate. A legitimate pharmacy makes each one easy to verify. A weak one answers the easy questions fully and the specific ones vaguely.

FAQ

How do I know if a pharmacy is legitimate? Verify the state license, the physical address, the phone number, the prescription requirement, and the named pharmacy contact.

What is the difference between 503A and 503B? 503A is patient-specific compounding under a state pharmacy model. 503B is an outsourcing facility model with different oversight and production rules.

Can a compounder call itself FDA approved? No. The FDA says compounded drugs are not FDA approved, and the agency warns telehealth marketers not to say otherwise.

Does the April 30, 2026 proposal end all 503B compounding? No. It is a proposal about the 503B bulks list, so it should be treated as a live rulemaking step, not a final exclusion.